GRAL stock forecast, quote, news & analysis
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection... Show more
GRAIL, Inc. (GRAL) Stock Analysis: Galleri Sales Momentum Sparks Analyst Upgrades Amid Biotech Volatility
Key Takeaways
- GRAIL reported Q3 2025 revenue of $36.2 million, a 26% year-over-year increase, driven by 39% growth in Galleri test sales to over 45,000 units.
- Analysts upgraded price targets, with Morgan Stanley raising to $110 and maintaining Equal-Weight, while Canaccord Genuity held Buy at $105.
- The stock experienced a 17.7% monthly decline, influenced by a large block trade and equity distribution agreement.
- SYMPLIFY study updates showed improved positive predictive value to 84.2%, bolstering confidence in Galleri's cancer detection accuracy.
- FDA premarket approval submission for Galleri delayed to Q1 2026, with cash position strengthened to over $850 million post-private placement.
- Conference presentations and inducement grants highlighted ongoing operational advancements in multi-cancer early detection.
Current Market Snapshot
GRAIL, Inc.'s stock has navigated heightened volatility in recent trading sessions, reflecting dynamics in the biotechnology and diagnostics sectors. After substantial gains earlier in the market cycle, shares have faced downward adjustments as investors evaluate clinical progress against valuation metrics. Trading toward the mid-range of its yearly spectrum, the stock appeals to those focused on innovative cancer screening technologies, supported by expanding test adoption. Market capitalization aligns with emerging healthcare firms, with liquidity facilitating moderate trading. The performance encapsulates the balance between promising data readouts and broader economic influences on growth-oriented equities.
AI Trading Bot Spotlight
The DGNX, NNE, KYIV, GRAL, PTRN, CGON, WBTN, MRX - Trading Results AI Trading Agent (8 Tickers), 60min from Tickeron applies an aggressive, high-frequency intraday strategy to volatile stocks including GRAL. On a 60-minute timeframe, it uses AI and machine learning from Tickeron's Financial Learning Models to spot technical breakouts, employing volatility indicators for precise long entries. The Breakout Acceleration Engine captures momentum changes, paired with a micro-floating stop-loss for risk control in dynamic conditions. Over 206 days of historical data, it achieved an annualized return of +80% on a $100,000 balance, demonstrating a favorable profit-to-dip ratio in high-volatility settings. Traders seeking automated tools may consider this bot to complement diversified strategies.
Recent Developments Driving GRAL Price Action
In the past 30 days, GRAIL, Inc. has been shaped by earnings momentum, analyst revisions, and financing activities that have contributed to stock volatility in the diagnostics space. The period began with the November 12 release of Q3 2025 financial results, showing revenue of $36.2 million, up 26% year-over-year, fueled by a 39% increase in Galleri multi-cancer early detection test sales to over 45,000 units. This growth reflected stronger adoption among healthcare providers, with screening revenue rising 29% to $32.8 million. The company reported a net loss of $89 million, improved from prior periods, and updated its full-year 2025 cash burn guidance to no more than $290 million. An earnings call highlighted enhanced SYMPLIFY study data, with positive predictive value rising to 84.2% after extended follow-up, reinforcing Galleri's clinical utility. This announcement triggered a 6% after-hours surge, as investors responded positively to commercial progress and a cash position bolstered to $850 million following an October private placement.
Following the earnings, GRAIL hosted its Analyst Day on November 13, providing insights into strategic priorities, including international expansions and a pending $110 million investment from Samsung. These updates supported initial gains, but momentum shifted with a November 14 equity distribution agreement for up to $300 million in shares, signaling potential dilution. On November 17, the stock rose nearly 7% amid broader market movers, coinciding with Canaccord Genuity maintaining a Buy rating and raising its price target to $105 from $85, citing robust test volumes.
However, sentiment turned cautious on November 18, when shares declined over 9% following a 1 million share block trade priced at $80.65, executed by Goldman Sachs. This event, amid an equity offering, amplified concerns over near-term supply pressure, contributing to intraday lows. Guggenheim reiterated its Buy rating that day, but the pullback persisted, with the stock down 17.7% over the month. A November 19 insider sale by the CFO added to the mixed signals, though it did not significantly alter the trajectory.
Analyst actions provided counterbalance, with Morgan Stanley raising its price target to $85 from $38 on November 16, then to $110 on December 2 while maintaining Equal-Weight. Coverage initiation on December 1 at Equal-Weight further underscored valuation debates. Consensus ratings lean toward Moderate Buy, with an average target of $105, ranging up to $110. These upgrades helped stabilize shares in early December, trading around $91.86 by December 24 after a 0.51% gain.
Industry catalysts included conference presentations, such as at the Piper Sandler 37th Annual Healthcare Conference in late November and the Wolfe Research event, where GRAIL emphasized Galleri's role in symptomatic populations. Inducement grants under NASDAQ rules on November 24 signaled talent retention efforts. No major regulatory shifts occurred, but the delayed FDA premarket approval submission to Q1 2026 introduced timeline risks, tempering optimism. Macroeconomic factors, like biotech sector softness amid interest rate uncertainties, exacerbated the monthly decline.
Overall, these events drove fluctuations, with the stock retreating from a 52-week high of $115.76 in late November, highlighting the interplay between operational advancements and financing dynamics.
2026 Outlook and Key Factors to Monitor
As GRAIL, Inc. progresses into 2026, investors should track the FDA premarket approval process for Galleri, anticipated in Q1, which could catalyze reimbursement discussions and broader market access in multi-cancer screening. Opportunities lie in scaling test volumes through provider partnerships and international initiatives, including the Samsung collaboration, amid growing demand for early detection diagnostics in a market emphasizing precision oncology.
Risks encompass regulatory delays or denials, potentially straining cash reserves despite the fortified balance sheet. Macroeconomic pressures, such as healthcare spending constraints from inflation or policy shifts, may impact adoption rates. Technology advancements in methylation-based platforms offer innovation potential but require sustained R&D investments to address cost structures and improve margins. Competitive positioning against peers in liquid biopsy will depend on clinical data differentiation and strategic alliances. Monitoring reimbursement progress, operational efficiencies, and global trade dynamics will be essential for assessing GRAIL's path in an evolving biotech landscape.
Momentum Indicator for GRAL turns negative, indicating new downward trend
GRAL saw its Momentum Indicator move below the 0 level on April 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator turned negative. In of the 30 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 20 cases where GRAL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRAL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for GRAL entered a downward trend on March 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GRAL's RSI Indicator exited the oversold zone, of 3 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for GRAL just turned positive on March 16, 2026. Looking at past instances where GRAL's MACD turned positive, the stock continued to rise in of 15 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRAL advanced for three days, in of 96 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.757) is normal, around the industry mean (12.312). P/E Ratio (0.000) is within average values for comparable stocks, (107.328). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.268). GRAL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (11.876) is also within normal values, averaging (16.743).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GRAL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRAL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement